These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32429322)

  • 1. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.
    Bosseboeuf A; Mennesson N; Allain-Maillet S; Tallet A; Piver E; Decaux O; Moreau C; Moreau P; Lehours P; Mégraud F; Salle V; Bigot-Corbel E; Harb J; Hermouet S
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429322
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
    Hermouet S; Bigot-Corbel E; Harb J
    Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens.
    Harb J; Mennesson N; Lepetit C; Fourny M; Louvois M; Bosseboeuf A; Allain-Maillet S; Decaux O; Moreau C; Tallet A; Piver E; Moreau P; Salle V; Bigot-Corbel E; Hermouet S
    Cells; 2021 Feb; 10(2):. PubMed ID: 33669483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.
    Bosseboeuf A; Seillier C; Mennesson N; Allain-Maillet S; Fourny M; Tallet A; Piver E; Lehours P; Mégraud F; Berthelot L; Harb J; Bigot-Corbel E; Hermouet S
    Front Immunol; 2020; 11():854. PubMed ID: 32536913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.
    Bosseboeuf A; Allain-Maillet S; Mennesson N; Tallet A; Rossi C; Garderet L; Caillot D; Moreau P; Piver E; Girodon F; Perreault H; Brouard S; Nicot A; Bigot-Corbel E; Hermouet S; Harb J
    Front Immunol; 2017; 8():1347. PubMed ID: 29098000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy.
    Nair S; Bar N; Xu ML; Dhodapkar M; Mistry PK
    Mol Genet Metab; 2020 Apr; 129(4):286-291. PubMed ID: 32044242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.
    Bosseboeuf A; Feron D; Tallet A; Rossi C; Charlier C; Garderet L; Caillot D; Moreau P; Cardó-Vila M; Pasqualini R; Arap W; Nelson AD; Wilson BS; Perreault H; Piver E; Weigel P; Girodon F; Harb J; Bigot-Corbel E; Hermouet S
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Damasceno D; Almeida J; Teodosio C; Sanoja-Flores L; Mayado A; Pérez-Pons A; Puig N; Arana P; Paiva B; Solano F; Romero A; Matarraz S; van den Bossche WBL; Flores-Montero J; Durie B; van Dongen JJM; Orfao A
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses.
    Rodríguez-García A; Mennesson N; Hernandez-Ibarburu G; Morales ML; Garderet L; Bouchereau L; Allain-Maillet S; Piver E; Marbán I; Rubio D; Bigot-Corbel E; Martínez-López J; Linares M; Hermouet S
    Haematologica; 2024 Jan; 109(1):272-282. PubMed ID: 37199121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.
    Ferla V; Farina F; Perini T; Marcatti M; Ciceri F
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.